580 First-in-human, Safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) Results From a Phase I Study of a Selective BRAF Inhibitor (BRAFi) RG7256 in Patients with BRAF V600-mutated Advanced Solid Tumors

✍ Scribed by Dienstmann, R.; Lassen, U.; Cebon, J.; Desai, J.; Brown, M.P.; Evers, S.; Su, F.; Zhang, W.; Meresse, V.; Tabernero, J.

• Book ID: 122650683
• Publisher: Elsevier Science
• Year: 2012
• Tongue: English
• Weight: 75 KB
• Volume: 48
• Category: Article
• ISSN: 0959-8049
• DOI: 10.1016/S0959-8049(12)72377-8